Tranexamic acid for childbirth: why, when, and for whom

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Maternal Health

Background:

• Postpartum hemorrhage (PPH) is a leading cause of maternal mortality and morbidity worldwide.
• Tranexamic acid, an antifibrinolytic, is recommended for PPH treatment, particularly when administered soon after delivery.
• Its efficacy and safety in high-income settings require further investigation.

Purpose of the Study:

• To evaluate the role of tranexamic acid in managing postpartum hemorrhage.
• To assess the evidence for the universal use of tranexamic acid in preventing PPH.
• To highlight the need for pharmacovigilance regarding tranexamic acid in high-income countries.

Main Methods:

• Review of existing literature on tranexamic acid for PPH treatment and prevention.
• Analysis of current treatment guidelines and recommendations.
• Emphasis on the importance of pharmacovigilance data.

Main Results:

• Tranexamic acid administration (1g IV, with a potential second dose) reduces bleeding-related mortality in PPH.
• Evidence supporting universal prophylactic use of tranexamic acid after vaginal or cesarean delivery is insufficient.
• Potential rare adverse events, such as renal failure, necessitate monitoring.

Conclusions:

• Early administration of tranexamic acid is recommended for PPH treatment.
• Further research is needed to establish the benefits of universal tranexamic acid prophylaxis for PPH.
• Pharmacovigilance is essential to monitor for adverse events in high-income populations receiving tranexamic acid for PPH.